Envoy Medical Receives Additional Patent Protection for its Innovative Approach to Hearing Loss
Envoy Medical (NASDAQ: COCH) has secured four new patents strengthening its position in hearing loss solutions. The company received US Patent No. 12,151,102 on November 25, 2024, and will be granted three European Patents (No. 4255554, 4255555, and 4319866) on January 1, 2025.
The patents cover innovative technologies including: a combination hearing aid and cochlear implant system, cochlear implant stimulation calibration, and electrode impedance diagnostics. These developments focus on improving signal processing, system calibration, and diagnostic capabilities in cochlear implant systems.
Envoy Medical (NASDAQ: COCH) ha ottenuto quattro nuovi brevetti che rafforzano la sua posizione nelle soluzioni per la perdita uditiva. L'azienda ha ricevuto il Brevetto Statunitense n. 12,151,102 il 25 novembre 2024 e verranno concessi tre Brevetti Europei (n. 4255554, 4255555 e 4319866) il 1 gennaio 2025.
I brevetti riguardano tecnologie innovative che includono: un sistema combinato di apparecchio acustico e impianto cocleare, calibrazione della stimolazione dell'impianto cocleare e diagnostica dell'impedenza degli elettrodi. Questi sviluppi si concentrano sul miglioramento dell'elaborazione dei segnali, della calibrazione del sistema e delle capacità diagnostiche negli impianti cocleari.
Envoy Medical (NASDAQ: COCH) ha asegurado cuatro nuevas patentes que refuerzan su posición en las soluciones para la pérdida auditiva. La compañía recibió la Patente de EE. UU. No. 12,151,102 el 25 de noviembre de 2024, y se le otorgarán tres Patentes Europeas (No. 4255554, 4255555 y 4319866) el 1 de enero de 2025.
Las patentes cubren tecnologías innovadoras que incluyen: un sistema combinado de audífono e implante coclear, calibración de estimulación del implante coclear y diagnóstico de impedancia de electrodos. Estos desarrollos se centran en mejorar el procesamiento de señales, la calibración del sistema y las capacidades de diagnóstico en sistemas de implantes cocleares.
Envoy Medical (NASDAQ: COCH)는 청각 손실 솔루션에서의 입지를 강화하는 네 개의 새로운 특허를 확보했습니다. 이 회사는 2024년 11월 25일 미국 특허 번호 12,151,102를 받았으며, 2025년 1월 1일에 세 개의 유럽 특허(번호 4255554, 4255555, 4319866)를 부여받을 예정입니다.
이 특허들은 다음과 같은 혁신적인 기술들을 포함합니다: 보청기와 인공 와우 시스템의 조합, 인공 와우 자극 보정, 전극 임피던스 진단. 이러한 발전들은 인공 와우 시스템에서 신호 처리, 시스템 보정 및 진단 능력을 개선하는 데 중점을 두고 있습니다.
Envoy Medical (NASDAQ: COCH) a obtenu quatre nouveaux brevets renforçant sa position dans les solutions de perte auditive. La société a reçu le brevet américain n° 12,151,102 le 25 novembre 2024, et trois brevets européens (n° 4255554, 4255555 et 4319866) seront accordés le 1er janvier 2025.
Les brevets concernent des technologies innovantes, y compris : un système combiné d'appareil auditif et d'implant cochléaire, la calibration de la stimulation de l'implant cochléaire, et le diagnostic de l'impédance des électrodes. Ces développements visent à améliorer le traitement du signal, la calibration des systèmes, et les capacités de diagnostic dans les systèmes d'implants cochléaires.
Envoy Medical (NASDAQ: COCH) hat vier neue Patente gesichert, die seine Position im Bereich der Lösungen für Hörverlust stärken. Das Unternehmen erhielt am 25. November 2024 das US-Patent Nr. 12,151,102 und wird am 1. Januar 2025 drei europäische Patente (Nr. 4255554, 4255555 und 4319866) erhalten.
Die Patente decken innovative Technologien ab, darunter: ein kombiniertes Hörgerät- und Cochlea-Implantat-System, Kalibrierung der Cochlea-Implantat-Stimulation und Diagnostik der Elektrodenimpedanz. Diese Entwicklungen konzentrieren sich auf die Verbesserung der Signalverarbeitung, der Systemkalibrierung und der diagnostischen Fähigkeiten von Cochlea-Implantatsystemen.
- Secured 4 new patents (1 US, 3 European) strengthening intellectual property portfolio
- Patents protect key technological innovations in hearing solutions
- None.
Insights
WHITE BEAR LAKE, Minnesota , Dec. 16, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on providing hearing loss suffers with innovative solutions today announces four new patents.
The US Patent & Trademark Office issued Envoy Medical Corporation US Pat. No. 12,151,102 on November 25, 2024. The title of the patent is Combination Hearing Aid and Cochlear Implant System. This patent relates to updating a transfer function associated with an implanted signal processor of a cochlear implant system to compensate for operation of an external auditory aid device, such as a hearing aid, that affects a stimulus received at an input source of the cochlear implant system and input signals representative of the stimulus.
The European Patent Office will grant European Patent No. 4255554 to Envoy Medical Corporation on January 1, 2025. The title is Combination Hearing Aid and Cochlear Implant System. This patent relates to cochlear implant systems and receiving a status indicator signal indicative of whether an external auditory aid device (e.g., a hearing aid) is active, and updating a transfer function of a signal processor of the cochlear implant system to compensate for operation of the external auditory aid device if it is active.
The European Patent Office will grant European Patent No. 4255555 to Envoy Medical Corporation on January 1, 2025. The title is Cochlear Implant Stimulation Calibration. This patent relates to calibrating current flow in a cochlear implant system. A switching network can be controlled to place a source element of a cochlear implant system in communication with a testing circuit. An amount of electrical current provided to the testing circuit can be determined, and the output of the source element can be adjusted based on the determined amount of electrical current.
The European Patent Office will grant European Patent No. 4319866 to Envoy Medical Corporation on January 1, 2025. The title is Cochlear Implant System with Electrode Impedance Diagnostics. This patent relates to electrode impedance diagnostics in cochlear implant systems. A cochlear implant system can determine an impedance associated with a current path from a source element to a return electrode and determine one or more stimulation parameters for the source element based on the impedance. An example stimulation parameter can include a compliance voltage for the source element to provide a prescribed current.
“We will continue to invest in the development and protection of intellectual property as we grow,” explained Brent Lucas, CEO of Envoy Medical, “We intend for Envoy Medical to be synonymous with meaningful innovation in the hearing loss industry for decades to come.”
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant (“Acclaim CI”) is a first-of-its-kind hearing device. Envoy Medical’s fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear’s natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can’t lose it. You don’t clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the ability to obtain additional patents and develop future products or product improvements, the Acclaim CI being the first to market fully implanted cochlear implant, the timing and results of clinical trials of the Acclaim CI, and the participation of any institution in such trials; the safety, performance, and market acceptance of the Acclaim CI; the size of Envoy Medical’s addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical’s current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical’s Class A Common Stock; changes in or removal of Envoy Medical’s shares inclusion in any index; Envoy Medical’s success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical’s suppliers, or disruptions in Envoy Medical’s own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical’s key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” in the Annual Report on Form 10-K filed by Envoy Medical on April 1, 2024, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical’s good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
###
Investor Relations:
Envoy Medical Investor Relations
(651) 361-8043
InvestorRelations@envoymedical.com
Media Contact:
Media@envoymedical.com
FAQ
What new patents did Envoy Medical (COCH) receive in December 2024?
What technology does Envoy Medical's US Patent 12,151,102 cover?
When will Envoy Medical's new European patents be granted?
What are the key innovations in Envoy Medical's new European patents?
